Commonwealth Equity Services’s Biolase, Inc. BIOL Stock Holding History

Commonwealth Equity Services’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-757	Closed	-$5K	–	3962
2023 Q2	$5K	Buy	757 +500	+195%	+$8.37K	﹤0.01%	3816
2023 Q1	$7	Buy	257 +150	+140%	+$7.3K	﹤0.01%	3738
2022 Q4	$6K	Buy	+107	New	+$15.4K	﹤0.01%	3674
2022 Q2	–	Sell	-40	Closed	-$35K	–	3828
2022 Q1	$35K	Buy	40 +21	+111%	+$19.4K	﹤0.01%	3616
2021 Q4	$18K	Sell	19 -1	-5%	-$1.26K	﹤0.01%	3610
2021 Q3	$31K	Buy	+20	New	+$32.6K	﹤0.01%	3529
2017 Q3	–	Sell	-1	Closed	-$12K	–	2625
2017 Q2	$12K	Hold	1	–	–	﹤0.01%	2502
2017 Q1	$17K	Hold	1	–	–	﹤0.01%	2396
2016 Q4	$17K	Hold	1	–	–	﹤0.01%	2294
2016 Q3	$22K	Hold	1	–	–	﹤0.01%	2217
2016 Q2	$15K	Hold	1	–	–	﹤0.01%	2214
2016 Q1	$16K	Hold	1	–	–	﹤0.01%	2177
2015 Q4	$10K	Buy	+1	New	+$10.9K	﹤0.01%	2170

Other funds holding BIOL

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Commonwealth Equity Services's BIOL Position: Q3 2023 in Review

Commonwealth Equity Services sold out of Biolase, Inc. (BIOL) in Q3 2023, closing a stake of 757 shares — an estimated $5K sold.

Commonwealth Equity Services first reported a position in BIOL in Q4 2015 and held it in 13 quarters. The position peaked at $35K in Q1 2022. 12 funds tracked by Wall St. Rank hold BIOL as of Q3 2023.

Commonwealth Equity Services reported no remaining Biolase, Inc. position as of Q3 2023 after selling out during the quarter.
Commonwealth Equity Services sold 757 Biolase, Inc. shares in Q3 2023, an estimated $5K.
Commonwealth Equity Services first reported a position in Biolase, Inc. in Q4 2015 and held it in 13 quarters.
Commonwealth Equity Services's Biolase, Inc. position peaked at $35K in Q1 2022.
12 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2023.

Based on Commonwealth Equity Services's 13F filing for Q3 2023, filed 23 Oct 2023.